Prizidilol (SK&F 92657; PZD), a new antihypertensive agent, possesses both vasodilator and beta-blocking properties. Twenty-four essential hypertensive patients were treated orally for 4 weeks with prizidilol (200-800 mg/die, o.d., Group A, or b.i.d. Group B). Blood pressure was significantly reduced in both groups: from 174 ± 13 115 ± 9 to 144 ± 10 94 ± 13 mm Hg supine, and from 169 ± 13 117 ± 9 to 141 ± 10 94 ± 10 mm Hg standing, in Group A; and from 178 ± 15 110 ± 6 to 149 ± 19 95 ± 12 mm Hg supine, and from 172 ± 18 114 ± 8 to 141.7 ± 17 98 ± 11 mm Hg standing, in Group B. Supine diastolic pressure reduction to 95 was achieved at the end of 4 weeks' treatment in 9 12 and 6 12 patients in Groups A and B, respectively. Heart rate was significantly reduced only in Group B, in the supine position (from 78 ±9 to 70 ±5 beats/min) and in the standing position (from 89 ± 9 to 76 ± 6 beats/min). However, there was no significant difference between the two groups. Prizidilol's effect on hormonal levels was assessed in the supine and standing positions in 16 patients. Plasma adrenaline and noradrenaline in the supine position increased significantly from 83 ± 16 to 205 ± 39 ng/L, and from 344 ± 51 to 640 ± 131 ng/L, respectively. Supine and standing plasma renin activity significantly decreased from 1.9 ± 0.4 ng/ml/h to 1.2 ± 0.3 ng/ml/h, and from 3.7 ± 0.8 to 1.5 ± 0.3 ng/ml/h, respectively. Plasma aldosterone concentrations decreased significantly in the standing position from 267 ± 27 to 122 ± 16 pg/ml. In 14 of the 24 patients, haemodynamic measurements were performed, before and after 4 weeks of PZD treatment. Cardiac and stroke indices increased slightly (from 3.39 ± 0.45 to 3.65 ± 0.45 L/min/m2 ± SD and from 46 ± 8 to 50 ± 6 ml/m2 ± SEM). Total peripheral resistance decreased significantly from 38 ± 7 to 31 ± 4 U/m2; plasma volume increased significantly from 3.1 ± 0.5 to 3.5 ± 0.2 litres. It is concluded that PZD is a well tolerated and effective agent in mild to moderate hypertension administered either as a single daily dose or by two doses daily. © 1984.
Effects of prizidilol (SK & F 92657) on haemodynamics, catecholamines and the renin-aldosterone-angiotensin system in essential hypertensive patients
Agabiti-Rosei E.;Boni E.;Muiesan M. L.;Romanelli G.;Castellano M.;
1984-01-01
Abstract
Prizidilol (SK&F 92657; PZD), a new antihypertensive agent, possesses both vasodilator and beta-blocking properties. Twenty-four essential hypertensive patients were treated orally for 4 weeks with prizidilol (200-800 mg/die, o.d., Group A, or b.i.d. Group B). Blood pressure was significantly reduced in both groups: from 174 ± 13 115 ± 9 to 144 ± 10 94 ± 13 mm Hg supine, and from 169 ± 13 117 ± 9 to 141 ± 10 94 ± 10 mm Hg standing, in Group A; and from 178 ± 15 110 ± 6 to 149 ± 19 95 ± 12 mm Hg supine, and from 172 ± 18 114 ± 8 to 141.7 ± 17 98 ± 11 mm Hg standing, in Group B. Supine diastolic pressure reduction to 95 was achieved at the end of 4 weeks' treatment in 9 12 and 6 12 patients in Groups A and B, respectively. Heart rate was significantly reduced only in Group B, in the supine position (from 78 ±9 to 70 ±5 beats/min) and in the standing position (from 89 ± 9 to 76 ± 6 beats/min). However, there was no significant difference between the two groups. Prizidilol's effect on hormonal levels was assessed in the supine and standing positions in 16 patients. Plasma adrenaline and noradrenaline in the supine position increased significantly from 83 ± 16 to 205 ± 39 ng/L, and from 344 ± 51 to 640 ± 131 ng/L, respectively. Supine and standing plasma renin activity significantly decreased from 1.9 ± 0.4 ng/ml/h to 1.2 ± 0.3 ng/ml/h, and from 3.7 ± 0.8 to 1.5 ± 0.3 ng/ml/h, respectively. Plasma aldosterone concentrations decreased significantly in the standing position from 267 ± 27 to 122 ± 16 pg/ml. In 14 of the 24 patients, haemodynamic measurements were performed, before and after 4 weeks of PZD treatment. Cardiac and stroke indices increased slightly (from 3.39 ± 0.45 to 3.65 ± 0.45 L/min/m2 ± SD and from 46 ± 8 to 50 ± 6 ml/m2 ± SEM). Total peripheral resistance decreased significantly from 38 ± 7 to 31 ± 4 U/m2; plasma volume increased significantly from 3.1 ± 0.5 to 3.5 ± 0.2 litres. It is concluded that PZD is a well tolerated and effective agent in mild to moderate hypertension administered either as a single daily dose or by two doses daily. © 1984.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
